QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide.
$50.33-1.04%
报价 2026-11-06
市值
$10.39B
EV
$11.26B
PE (TTM)
25.8x
预期 PE (FY2026)
20.7x
52 周区间距高点 -9.6%
$32.63$55.66
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
L2 2026-07-09全文 ↓尚未生成 L3 估值，没有三情景目标价。去生成估值 →
L2 报告格式无法提取要点，请看全文。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Diagnostics & Research| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| QGENQiagen N.V. | $10.39B | -1.0% | +2.8% | 63.6% | 25.8x | 16.0x | 23.2x | |
| MEDPMedpace Holdings, Inc. | $18.27B | +2.9% | +13.5% | 31.3% | 36.9x | 28.6x | 28.4x | |
| RVTYRevvity, Inc. | $17.31B | +2.8% | +0.6% | 57.1% | 72.2x | 25.1x | 30.3x | |
| CRLCharles River Laboratories International, Inc. | $16.17B | +7.8% | -2.2% | 36.2% | – | 91.3x | 46.6x | |
| ICLRICON Public Limited Company | $15.34B | +1.5% | +1.6% | 19.6% | 34.7x | 13.4x | 12.2x | |
| TWSTTwist Bioscience Corporation | $7.95B | +0.1% | +20.2% | 52.8% | – | – | – | |
| RDNTRadNet, Inc. | $5.98B | -2.6% | +24.9% | 14.1% | – | 26.8x | – | |
| GRALGRAIL, Inc. | $5.42B | +1.9% | +23.1% | -28.1% | – | – | – | |
| BLLNBillionToOne, Inc. | $5.38B | +1.4% | +53.5% | 70.9% | 111.0x | 83.9x | 158.6x | 高增长 |
| 同行中位数 | – | – | +16.8% | 33.7% | 54.6x | 27.7x | 30.3x |
研究全文
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $535M | $492.3M | $540.4M | $532.6M | $533.5M | $483.5M | $521.2M | $501.9M |
| Gross Margin | 63.6% | 62.9% | 58.7% | 62.2% | 62.7% | 63.8% | 63.9% | 61.4% |
| Operating Margin | 24.7% | 23.7% | 28.5% | 24.3% | 22.8% | 23.9% | 22.9% | 22.3% |
| Net Income | $103.4M | $68M | $107.8M | $130M | $96.3M | $90.8M | $88.3M | $98.1M |
| Diluted EPS | 0.5 | 0.33 | 0.52 | 0.6 | 0.44 | 0.41 | 0.41 | 0.44 |
| Operating Cash Flow | $200.7M | $100.6M | $188.1M | $165M | $161.4M | $139.7M | $191.5M | $182.3M |